Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus oral vinorelbine in pretreated metastatic HER2-negative breast cancer
NCT02768415Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in breast cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02768415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768415.